36
Participants
Start Date
June 23, 2024
Primary Completion Date
June 23, 2027
Study Completion Date
June 23, 2027
Orelabrutinib in combination with rituximab
"Induction Phase:~Orelabrutinib + rituximab for a total of 6 cycles of 28 days each Obrutinib (O) 150mg oral d1-28 Rituximab (R) 375mg/m2 IV d0~Maintenance phase:~Orelabrutinib 150mg po qd 24 cycles of 28 days each"
RECRUITING
Bing, Xu, Xiamen
The First Hospital of Jilin University
OTHER
Fujian Cancer Hospital
OTHER_GOV
Guangdong Provincial People's Hospital
OTHER
Nanfang Hospital, Southern Medical University
OTHER
The Second Affiliated Hospital of Dalian Medical University
OTHER
Jiangxi Provincial Cancer Hospital
OTHER
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
OTHER
Shaanxi Provincial Cancer Hospital
OTHER
Chinese PLA General Hospital
OTHER
The First Affiliated Hospital of Xiamen University
OTHER